Literature DB >> 26261495

Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma.

Kai-Lian Zheng1, Tian-Lin He1, Wei-Ping Ji1, Hui Jiang2, Ye Shen3, Gang Li1, Si-Bo Zhu2, Bing-Lei Tong2, Yi-Jie Zhang1.   

Abstract

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is the most common form of malignancy in pancreatic carcinoma. Here we report our discovery on the correlations between transcriptional alternative splicing (AS) of NUMB, APP, VEGFA and PDAC in patients.
METHODS: The expression of NUMB, APP, VEGFA from patient samples was determined by qRT-PCR. AS of these genes was examined through laser induced fluorescence capillary electrophoresis. Correlation between the AS of the genes and results from clinical laboratory examinations were analyzed. Expression of NOTHC1 and NOTCH4 as downstream target genes was examined by qRT-PCR and Western blot.
RESULTS: Quantitative results indicated that expression of NUMB was significantly lower in tumor tissues (TT) than in para-tumor tissues (TP) (P<0.05), while APP (P<0.01) and VEGFA (P<0.05) were significantly higher. AS transcript percentage of NUMB PRR(S) was lower in TT than TP (P<0.05). AS transcript percentage of VEGFA (105+185) was significantly lower in TT than TP (P<0.05) compared to higher expression of VEGFA (206+338) (P<0.05). Regression analysis indicated that AS transcript of NUMB PRR(L) correlated with tumor size (P<0.01), while AS transcripts of APP and VEGFA correlated with results of laboratory examinations. To reveal the correlation between AS and its downstream targets, NOTCH1 and NOTCH4 were selected as NUMB gene targets and detected to be significantly higher in TT than TP (P<0.05).
CONCLUSION: Alternative splicing of APP, VEGFA and NUMB may play an important role in pathogenesis of pancreatic ductal adenocarcinoma. Among the 3 genes, PRR(L) form of NUMB gene is highly expressed in TT and positively correlated with tumor size, while PRR(S) is lacking in TT and negatively correlated with NOTCH expression suggesting that PRR(S) might be protective in tumorogenesis and shows NOTCH pathway down regulation ability.

Entities:  

Keywords:  Alternative splicing; NUMB; pancreatic ductal carcinoma

Mesh:

Substances:

Year:  2015        PMID: 26261495      PMCID: PMC4525829     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  20 in total

Review 1.  Pre-mRNA processing reaches back to transcription and ahead to translation.

Authors:  Melissa J Moore; Nick J Proudfoot
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

2.  Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer.

Authors:  Christine M Misquitta-Ali; Edith Cheng; Dave O'Hanlon; Ni Liu; C Jane McGlade; Ming Sound Tsao; Benjamin J Blencowe
Journal:  Mol Cell Biol       Date:  2010-11-01       Impact factor: 4.272

Review 3.  Current standards of surgery for pancreatic cancer.

Authors:  N Alexakis; C Halloran; M Raraty; P Ghaneh; R Sutton; J P Neoptolemos
Journal:  Br J Surg       Date:  2004-11       Impact factor: 6.939

Review 4.  NUMB-ing down cancer by more than just a NOTCH.

Authors:  Salvatore Pece; Stefano Confalonieri; Pascale R Romano; Pier Paolo Di Fiore
Journal:  Biochim Biophys Acta       Date:  2010-10-16

Review 5.  Splicing in oncogenesis and tumor suppression.

Authors:  Daisuke Kaida; Tilman Schneider-Poetsch; Minoru Yoshida
Journal:  Cancer Sci       Date:  2012-07-24       Impact factor: 6.716

6.  Regulation of vertebrate nervous system alternative splicing and development by an SR-related protein.

Authors:  John A Calarco; Simone Superina; Dave O'Hanlon; Mathieu Gabut; Bushra Raj; Qun Pan; Ursula Skalska; Laura Clarke; Danielle Gelinas; Derek van der Kooy; Mei Zhen; Brian Ciruna; Benjamin J Blencowe
Journal:  Cell       Date:  2009-09-04       Impact factor: 41.582

Review 7.  The spliceosome as a target of novel antitumour drugs.

Authors:  Sophie Bonnal; Luisa Vigevani; Juan Valcárcel
Journal:  Nat Rev Drug Discov       Date:  2012-11       Impact factor: 84.694

8.  RNA interference‑mediated inhibition of survivin and VEGF in pancreatic cancer cells in vitro.

Authors:  Jianlin Song; Lipin Cao; Yixiong Li
Journal:  Mol Med Rep       Date:  2013-03-06       Impact factor: 2.952

9.  p53 is activated in response to disruption of the pre-mRNA splicing machinery.

Authors:  N Allende-Vega; S Dayal; U Agarwala; A Sparks; J-C Bourdon; M K Saville
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

Review 10.  RNA and disease.

Authors:  Thomas A Cooper; Lili Wan; Gideon Dreyfuss
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

View more
  4 in total

1.  Numb exon 9 inclusion regulates Integrinβ5 surface expression and promotes breast cancer metastasis.

Authors:  Yangjing Zhang; Sascha E Dho; Kamal Othman; Craig D Simpson; Jessica Lapierre; Andrew Bondoc; C Jane McGlade
Journal:  Oncogene       Date:  2022-02-18       Impact factor: 8.756

2.  ATP11A promotes EMT by regulating Numb PRRL in pancreatic cancer cells.

Authors:  Lin Chen; Jingtong Tang; Weiwei Sheng; Jian Sun; Yuteng Ma; Ming Dong
Journal:  PeerJ       Date:  2022-03-23       Impact factor: 2.984

3.  Identification of novel HNF1B mRNA splicing variants and their qualitative and semi-quantitative profile in selected healthy and tumour tissues.

Authors:  Jan Hojny; Michaela Bartu; Eva Krkavcova; Kristyna Nemejcova; Jan Sevcik; David Cibula; Vladimir Fryba; Lenka Plincelnerova; Pavel Dundr; Ivana Struzinska
Journal:  Sci Rep       Date:  2020-04-24       Impact factor: 4.379

4.  Amyloid Beta (A4) Precursor Protein: A Potential Biomarker for Recurrent Nasopharyngeal Carcinoma.

Authors:  Xiao-Yu Li; Hui-Ling Meng; Kai-Guo Li; Xiao-Hui Yang; Xiao-Dong Zhu; Ling Li; Zhong-Guo Liang; Xin-Bin Pan; Fan-Yan Zeng; Song Qu
Journal:  Cancer Manag Res       Date:  2019-12-20       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.